^
Association details:
| Biomarker: | HRAS H27_28fs* |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
Published date:
07/07/2020
Excerpt:
With a median follow-up of 28 months, 4 patients (19%) reached PFS6: 3 had missense HRAS mutations and one patient, enrolled as a STK11 carrier, had HRAS frameshift insertions at H27fs and H28fs rendering a nonsense HRAS mutation. Oral tipifarnib resulted in manageable safety profile and encouraging antitumor efficacy against treatment-refractory UC containing HRAS mutations.
DOI:
10.1158/1078-0432.CCR-20-1246
